Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC

Non-small cell lung cancer (NSCLC) accounts for a large proportion of cancer deaths and is characterized by low treatment response rates and poor overall prognosis. In the absence of specific treatable mutations, cisplatin-based chemotherapy plays an important role in the treatment of this disease....

Descripción completa

Detalles Bibliográficos
Autores principales: MacDonagh, Lauren, Gallagher, Michael F., Ffrench, Brendan, Gasch, Claudia, Breen, Eamon, Gray, Steven G., Nicholson, Siobhan, Leonard, Niamh, Ryan, Ronan, Young, Vincent, O'Leary, John J., Cuffe, Sinead, Finn, Stephen P., O'Byrne, Kenneth J., Barr, Martin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641151/
https://www.ncbi.nlm.nih.gov/pubmed/29069808
http://dx.doi.org/10.18632/oncotarget.19881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641151/
https://www.ncbi.nlm.nih.gov/pubmed/29069808
http://dx.doi.org/10.18632/oncotarget.19881

Ejemplares similares